Animal Model Market Trends – Analysis Report, 2032

Animal Model Market Size - Animal Type (Mice, Rats, Fish, Birds), Technology (CRISPR, Microinjection), Application (Research & Development), Use (Human, Veterinary), End-use, (Companies, Contract Research Organizations), Forecast 2023 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definition

1.2&nbsp;&nbsp;&nbsp; Base estimates and working

1.3&nbsp;&nbsp;&nbsp; Forecast parameters

1.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis at global level

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Unpaid sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Animal model industry 3600 synopsis, 2018 - 2032

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Regional trends

2.1.3&nbsp;&nbsp;&nbsp; Animal type trends

2.1.4&nbsp;&nbsp;&nbsp; Technology trends

2.1.5&nbsp;&nbsp;&nbsp; Application trends

2.1.6&nbsp;&nbsp;&nbsp; Use trends

2.1.7&nbsp;&nbsp;&nbsp; End-use trends

Chapter 3&nbsp;&nbsp;&nbsp;Animal Model Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry segmentation

3.2&nbsp;&nbsp;&nbsp; Industry landscape, 2018 &ndash; 2032 (USD Million)

3.3&nbsp;&nbsp;&nbsp; Industry impact forces

3.3.1&nbsp;&nbsp;&nbsp; Growth drivers

3.3.1.1&nbsp;&nbsp;&nbsp;Growing number of pharmaceutical research and development activities

3.3.1.2&nbsp;&nbsp;&nbsp;Increasing application areas of animal model in different research areas

3.3.1.3&nbsp;&nbsp;&nbsp;Physiological similarities between human and animal

3.3.1.4&nbsp;&nbsp;&nbsp;Emergence of CRISPR as a powerful tool in the field of biomedical research

3.3.1.5&nbsp;&nbsp;&nbsp;Growing consumption of personalized medicine driving the demand for humanized mice models

3.3.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.3.2.1&nbsp;&nbsp;&nbsp;High maintenance cost of animal models

3.3.2.2&nbsp;&nbsp;&nbsp;Strict regulations and guidelines

3.3.2.3&nbsp;&nbsp;&nbsp;Growing opposition on animal testing by several organizations

3.4&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4.1&nbsp;&nbsp;&nbsp; By animal type

3.4.2&nbsp;&nbsp;&nbsp; By technology

3.4.3&nbsp;&nbsp;&nbsp; By application

3.4.4&nbsp;&nbsp;&nbsp; By use

3.4.5&nbsp;&nbsp;&nbsp; By end-use

3.5&nbsp;&nbsp;&nbsp; COVID-19 impact analysis

3.6&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6.1&nbsp;&nbsp;&nbsp; U.S.

3.6.2&nbsp;&nbsp;&nbsp; Europe

3.6.3&nbsp;&nbsp;&nbsp; Asia Pacific

3.6.4&nbsp;&nbsp;&nbsp; Latin America

3.6.5&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

3.7&nbsp;&nbsp;&nbsp; Pricing analysis, 2022

3.8&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.9&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players, 2022

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategic outlook matrix

4.6&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Animal Model Market Estimates &amp; Forecast, By Animal Type (USD Million &amp; Units)

5.1&nbsp;&nbsp;&nbsp; Key trends, animal type

5.2&nbsp;&nbsp;&nbsp; Mice

5.3&nbsp;&nbsp;&nbsp; Rats

5.4&nbsp;&nbsp;&nbsp; Fish

5.5&nbsp;&nbsp;&nbsp; Birds

5.6&nbsp;&nbsp;&nbsp; Cattle

5.7&nbsp;&nbsp;&nbsp; Pigs

5.8&nbsp;&nbsp;&nbsp; Amphibians

5.9&nbsp;&nbsp;&nbsp; Guinea Pigs

5.10&nbsp;&nbsp;&nbsp; Dogs

5.11&nbsp;&nbsp;&nbsp; Cats

5.12&nbsp;&nbsp;&nbsp; Rabbits

5.13&nbsp;&nbsp;&nbsp; Monkeys

5.14&nbsp;&nbsp;&nbsp; Sheep

5.15&nbsp;&nbsp;&nbsp; Hamsters

5.16&nbsp;&nbsp;&nbsp; Other animal types

Chapter 6&nbsp;&nbsp;&nbsp;Animal Model Market Estimates &amp; Forecast, By Technology (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, technology

6.2&nbsp;&nbsp;&nbsp; CRISPR

6.3&nbsp;&nbsp;&nbsp; Microinjection

6.4&nbsp;&nbsp;&nbsp; Embryonic Stem Cell Injection

6.5&nbsp;&nbsp;&nbsp; Nuclear Transfer

6.6&nbsp;&nbsp;&nbsp; Other technologies

Chapter 7&nbsp;&nbsp;&nbsp;Animal Model Market Estimates &amp; Forecast, By Application (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, application

7.2&nbsp;&nbsp;&nbsp; Research &amp; Development

7.2.1&nbsp;&nbsp;&nbsp; Infectious Diseases

7.2.2&nbsp;&nbsp;&nbsp; Immunological Diseases

7.2.3&nbsp;&nbsp;&nbsp; Cancer

7.2.4&nbsp;&nbsp;&nbsp; Cardiovascular Diseases

7.2.5&nbsp;&nbsp;&nbsp; Diabetes

7.2.6&nbsp;&nbsp;&nbsp; Genetic Diseases

7.2.7&nbsp;&nbsp;&nbsp; Neurological Diseases

7.2.8&nbsp;&nbsp;&nbsp; Obesity

7.2.9&nbsp;&nbsp;&nbsp; NAFLD/NASH

7.2.10&nbsp;&nbsp;&nbsp; Renal disease

7.2.11&nbsp;&nbsp;&nbsp; Diabetic eye disease

7.2.12&nbsp;&nbsp;&nbsp; Fibrosis

7.2.13&nbsp;&nbsp;&nbsp; Microbiome

7.2.14&nbsp;&nbsp;&nbsp; Other research &amp; development applications

7.3&nbsp;&nbsp;&nbsp; Production and Quality Control

7.4&nbsp;&nbsp;&nbsp; Academics

7.5&nbsp;&nbsp;&nbsp; Preclinical Applications

7.5.1&nbsp;&nbsp;&nbsp; Infectious Disease

7.5.2&nbsp;&nbsp;&nbsp; Immunological Diseases

7.5.3&nbsp;&nbsp;&nbsp; Cancer

7.5.4&nbsp;&nbsp;&nbsp; Cardiovascular Diseases

7.5.5&nbsp;&nbsp;&nbsp; Diabetes

7.5.6&nbsp;&nbsp;&nbsp; Genetic Diseases

7.5.7&nbsp;&nbsp;&nbsp; Neurological Diseases

7.5.8&nbsp;&nbsp;&nbsp; Obesity

7.5.9&nbsp;&nbsp;&nbsp; NAFLD/NASH

7.5.10&nbsp;&nbsp;&nbsp; Renal disease

7.5.11&nbsp;&nbsp;&nbsp; Diabetic eye disease

7.5.12&nbsp;&nbsp;&nbsp; Fibrosis

7.5.13&nbsp;&nbsp;&nbsp; Microbiome

7.5.14&nbsp;&nbsp;&nbsp; Other preclinical applications

7.6&nbsp;&nbsp;&nbsp; Other applications

Chapter 8&nbsp;&nbsp;&nbsp;Animal Model Market Estimates &amp; Forecast, By Use (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, use

8.2&nbsp;&nbsp;&nbsp; Human

8.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

8.3&nbsp;&nbsp;&nbsp; Veterinary

8.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 9&nbsp;&nbsp;&nbsp;Animal Model Market Estimates &amp; Forecast, By End-use (USD Million)

9.1&nbsp;&nbsp;&nbsp; Key trends, end-use

9.2&nbsp;&nbsp;&nbsp; Companies

9.2.1&nbsp;&nbsp;&nbsp; Pharmaceutical

9.2.2&nbsp;&nbsp;&nbsp; Biotechnology

9.2.3&nbsp;&nbsp;&nbsp; Cosmetics

9.2.4&nbsp;&nbsp;&nbsp; Other companies

9.3&nbsp;&nbsp;&nbsp; Organizations

9.3.1&nbsp;&nbsp;&nbsp; Government

9.3.2&nbsp;&nbsp;&nbsp; Non-government

9.4&nbsp;&nbsp;&nbsp; Academic &amp; Research Institutes

9.5&nbsp;&nbsp;&nbsp; Contract Research Organizations

Chapter 10&nbsp;&nbsp;&nbsp;Animal Model Market Estimates &amp; Forecast, By Region (USD Million)

10.1&nbsp;&nbsp;&nbsp; Key trends, region

10.2&nbsp;&nbsp;&nbsp; North America

10.2.1&nbsp;&nbsp;&nbsp; U.S.

10.2.2&nbsp;&nbsp;&nbsp; Canada

10.3&nbsp;&nbsp;&nbsp; Europe

10.3.1&nbsp;&nbsp;&nbsp; Germany

10.3.2&nbsp;&nbsp;&nbsp; UK

10.3.3&nbsp;&nbsp;&nbsp; France

10.3.4&nbsp;&nbsp;&nbsp; Spain

10.3.5&nbsp;&nbsp;&nbsp; Italy

10.3.6&nbsp;&nbsp;&nbsp; Switzerland

10.3.7&nbsp;&nbsp;&nbsp; Netherlands

10.3.8&nbsp;&nbsp;&nbsp; Czech Republic

10.3.9&nbsp;&nbsp;&nbsp; Poland

10.3.10&nbsp;&nbsp;&nbsp; Belgium

10.3.11&nbsp;&nbsp;&nbsp; Finland

10.3.12&nbsp;&nbsp;&nbsp; Hungary

10.3.13&nbsp;&nbsp;&nbsp; Denmark

10.3.14&nbsp;&nbsp;&nbsp; Ireland

10.3.15&nbsp;&nbsp;&nbsp; Sweden

10.4&nbsp;&nbsp;&nbsp; Asia Pacific

10.4.1&nbsp;&nbsp;&nbsp; China

10.4.2&nbsp;&nbsp;&nbsp; Japan

10.4.3&nbsp;&nbsp;&nbsp; Australia

10.4.4&nbsp;&nbsp;&nbsp; South Korea

10.4.5&nbsp;&nbsp;&nbsp; New Zealand

10.4.6&nbsp;&nbsp;&nbsp; Taiwan

10.5&nbsp;&nbsp;&nbsp; Latin America

10.5.1&nbsp;&nbsp;&nbsp; Brazil

10.5.2&nbsp;&nbsp;&nbsp; Argentina

10.5.3&nbsp;&nbsp;&nbsp; Mexico

10.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

10.6.1&nbsp;&nbsp;&nbsp; South Africa

10.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

10.6.3&nbsp;&nbsp;&nbsp; UAE

10.6.4&nbsp;&nbsp;&nbsp; Israel

Chapter 11&nbsp;&nbsp;&nbsp;Company Profiles

11.1&nbsp;&nbsp;&nbsp; Charles River Laboratories

11.2&nbsp;&nbsp;&nbsp; Envigo

11.3&nbsp;&nbsp;&nbsp; genOway

11.4&nbsp;&nbsp;&nbsp; Harbour BioMed

11.5&nbsp;&nbsp;&nbsp; Janvier Labs

11.6&nbsp;&nbsp;&nbsp; PharmaLegacy

11.7&nbsp;&nbsp;&nbsp; Taconic Biosciences Inc.

11.8&nbsp;&nbsp;&nbsp; The Jackson Laboratory

11.9&nbsp;&nbsp;&nbsp; TRANS GENIC INC, Ltd. 
&nbsp;

Animal Model Market

Inquiry Before Buying